Osteoporosis - Pharmacologic Therapy Options

Pharmacologic Treatment of Osteoporosis When to Start Pharmacologic Treatment Before starting any medication, clinicians use specific criteria to determine which patients need pharmacologic therapy. Medication is recommended for: Any patient with a prior hip or spine fracture caused by osteoporosis Patients with very low bone density: A T-score of -2.5 or lower (meaning bone density is at or below 2.5 standard deviations below the young-adult mean) Patients with moderately low bone density and high fracture risk: A T-score between -1 and -2.5 AND a 10-year hip fracture risk of at least 3% according to the Fracture Risk Assessment Tool (FRAX) The key insight here is that medication isn't prescribed based solely on low bone density—clinicians must also consider fracture risk. Even someone with T-score between -1 and -2.5 might benefit from treatment if they have other risk factors that increase their likelihood of breaking a hip. Bisphosphonates: The First-Line Treatment Bisphosphonates are a class of medications that slow bone loss and remain the most commonly prescribed treatment for osteoporosis. Common examples include alendronate and risedronate. How They Work Bisphosphonates work by slowing the activity of osteoclasts—the cells responsible for breaking down bone. By reducing bone resorption, they help maintain bone density and reduce fracture risk. Effectiveness Bisphosphonates are particularly effective in patients with a prior osteoporotic fracture: Fracture risk reduction ranges from 25% to 70% depending on which bone is affected (hip fractures see greater risk reduction than vertebral fractures) Duration of benefit: The fracture risk reduction lasts for approximately 3-4 years Important limitation: Their effectiveness is less clear in patients without a previous fracture Mortality: Bisphosphonates do not reduce overall mortality Available Formulations Bisphosphonates come in two main forms: Oral bisphosphonates: Common, convenient, but must be taken correctly (upright position, empty stomach) Intravenous bisphosphonates: Less frequent dosing (annual or quarterly), better for patients with absorption problems Treatment Duration One confusing aspect of bisphosphonate therapy is knowing when to stop. The evidence suggests: After 5 years of oral bisphosphonate therapy in patients at low risk of fracture, the medication can be discontinued After 3 years of intravenous therapy in low-risk patients, treatment can be stopped Importantly, bone mineral density (BMD) does not need to be re-tested while the patient is on treatment—clinicians simply continue the medication as prescribed Rare But Important Adverse Effects Long-term bisphosphonate use is associated with two serious adverse effects, though both are uncommon: Atypical femoral fractures: These are unusual fractures of the thighbone that occur below the hip. While extremely rare, they represent a paradoxical effect where long-term use may weaken certain parts of the bone. Osteonecrosis of the jaw (ONJ): This is death of bone tissue in the jawbone, also rare but serious. Patients should maintain good dental hygiene and inform dentists about bisphosphonate use. Despite these rare complications, bisphosphonates remain safe and effective for most patients when used as directed. Calcium and Vitamin D Supplementation Calcium and vitamin D are essential minerals for bone health, but their role in osteoporosis treatment is more limited than many patients assume. What the Evidence Shows Combined calcium and vitamin D together may modestly reduce fracture risk—this combination is recommended, especially for patients at high risk Vitamin D alone is NOT effective: doses of 800 IU per day or less show no fracture risk reduction. (Higher doses are needed, but these aren't typically recommended as monotherapy) Calcium alone does not improve bone mineral density in premenopausal women and shows limited benefit overall Safety: Neither calcium nor vitamin D supplementation increases overall mortality Clinical Recommendations Calcium and vitamin D supplementation is recommended as a preventive foundation, particularly for: Patients on glucocorticoids (which increase bone loss) Older adults with limited sun exposure Patients who are being treated with other osteoporosis medications (as adjunctive therapy) Think of calcium and vitamin D as supporting therapy rather than primary treatment. They work best when combined with medications like bisphosphonates. Alternative Pharmacologic Options Several other medications are available for treating osteoporosis when bisphosphonates are not suitable or when additional fracture risk reduction is needed. Teriparatide (Parathyroid Hormone Analog) Teriparatide is a recombinant form of parathyroid hormone (PTH) that works differently from bisphosphonates. Instead of slowing bone loss, it stimulates bone formation, actually building new bone. It is effective for treating postmenopausal osteoporosis and is particularly useful for patients with very high fracture risk. Denosumab (Monoclonal Antibody Against RANKL) Denosumab is a newer class of medication that targets the RANK ligand (RANKL), a protein involved in bone resorption. It effectively prevents fractures in women with osteoporosis. However, evidence for benefit in men is more limited, so it's primarily used in postmenopausal women. Selective Estrogen Receptor Modulators (SERMs): Raloxifene Raloxifene is a SERM that acts like estrogen in bone but not in breast tissue. Key effects include: Decreases vertebral fracture risk Lowers breast cancer incidence (a bonus benefit) Important drawback: Increases the risk of blood clots (venous thromboembolism) and stroke Raloxifene is reserved for women at high breast cancer risk who also have osteoporosis. Strontium Ranelate Strontium ranelate reduces both vertebral and non-vertebral fracture risk in postmenopausal women. This dual benefit makes it useful in some cases, though it's not typically first-line therapy. <extrainfo> Other Options (Less Commonly Used) Romosozumab is a monoclonal antibody against sclerostin that simultaneously inhibits bone resorption (slows bone loss) and stimulates bone formation (builds new bone). This dual mechanism makes it powerful, but it is reserved only for patients at very high fracture risk due to potential cardiovascular concerns. Hormone Replacement Therapy (HRT) is effective for preventing bone loss in postmenopausal women, but it is not recommended as sole osteoporosis treatment. It should only be used when there are additional indications for HRT, such as moderate-to-severe menopausal symptoms, and requires individualized risk-benefit analysis. </extrainfo> Medications NOT Recommended Two medications that were historically used are no longer recommended: Fluoride supplementation: While fluoride increases bone density on X-rays, it does NOT reduce fracture risk in patients with osteoporosis. In fact, the bone formed may be abnormally structured and weak. Therefore, fluoride is not recommended for postmenopausal osteoporosis. Calcitonin: This hormone was previously used to slow bone loss, but it is no longer recommended because of a possible increased cancer risk and uncertain fracture benefit. Safer alternatives are now available. Key Takeaways The pharmacologic treatment of osteoporosis involves multiple options tailored to individual patient characteristics: Bisphosphonates remain first-line therapy for most patients, particularly those with prior fractures Calcium and vitamin D provide important supportive therapy but are not sufficient alone Treatment decisions are based on bone density scores, fracture risk assessment, and prior fracture history Duration of therapy is defined—patients on bisphosphonates can discontinue after 5 years (oral) or 3 years (IV) if at low risk Alternative agents offer options for patients who cannot tolerate bisphosphonates or have very high fracture risk Some historical treatments have been abandoned due to lack of efficacy or safety concerns The goal is to select the most effective medication with the fewest side effects for each individual patient's risk profile.